{"id":3127,"date":"2026-07-31T20:25:23","date_gmt":"2026-07-31T23:25:23","guid":{"rendered":"https:\/\/naturalmedicalpost.com\/blog\/ziltivekimab-novo-nordisk-s-fails\/"},"modified":"2026-07-31T20:25:23","modified_gmt":"2026-07-31T23:25:23","slug":"ziltivekimab-novo-nordisk-s-fails","status":"publish","type":"post","link":"https:\/\/naturalmedicalpost.com\/blog\/ziltivekimab-novo-nordisk-s-fails\/","title":{"rendered":"Novo Nordisk&#8217;s Ziltivekimab fails heart disease trial"},"content":{"rendered":"<aside class=\"medical-disclaimer\" style=\"border-left:4px solid #d97706;background:#fef3c7;padding:12px 16px;margin:16px 0;font-size:0.92em;color:#78350f;border-radius:4px\"><strong>&#9888; <\/strong><span>This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.<\/span><\/aside>\n<p>Novo Nordisk enfrentou um rev\u00e9s cl\u00ednico na sexta-feira, ao relatar que seu medicamento anti-inflamat\u00f3rio experimental, ziltivekimab, n\u00e3o reduziu o risco de eventos card\u00edacos graves em um estudo fundamental de Fase 3. <strong>Al\u00e9m disso,<\/strong> o an\u00fancio, baseado em um estudo com mais de 6.300 participantes, marca um momento significativo na busca cont\u00ednua de atacar a inflama\u00e7\u00e3o como forma de prevenir complica\u00e7\u00f5es cardiovasculares. <strong>Portanto,<\/strong> os achados destacam a lacuna entre as medidas laboratoriais de inflama\u00e7\u00e3o e os desfechos reais nos pacientes.<\/p>\n<h2>Desenho do Estudo e Altas Expectativas<\/h2>\n<p>O estudo de Fase 3 foi desenhado para incluir indiv\u00edduos com alta carga de doen\u00e7a: cada participante tinha doen\u00e7a card\u00edaca estabelecida, doen\u00e7a renal coexistente e evid\u00eancia de inflama\u00e7\u00e3o cr\u00f4nica. <strong>Para esse fim,<\/strong> o ziltivekimab, um anticorpo monoclonal que inibe a interleucina-6, foi visto como um candidato promissor para acalmar os processos inflamat\u00f3rios que se acredita acelerarem a aterosclerose e desencadearem ataques card\u00edacos. <strong>Al\u00e9m disso,<\/strong> mais de 6.300 pessoas foram inscritas, tornando-se um conjunto de dados robusto para tirar conclus\u00f5es. <strong>Ademais,<\/strong> pesquisas anteriores, incluindo o estudo marcante CANTOS, haviam sugerido que a terapia anti-inflamat\u00f3ria poderia reduzir eventos cardiovasculares, portanto a comunidade cardiol\u00f3gica tinha grandes esperan\u00e7as neste novo agente.<\/p>\n<p>Novo Nordisk, empresa renomada por seus medicamentos metab\u00f3licos, pretendia expandir para a inflama\u00e7\u00e3o cardiovascular. <strong>Especificamente,<\/strong> o desfecho prim\u00e1rio foi um composto de eventos card\u00edacos adversos maiores: morte relacionada a doen\u00e7a cardiovascular, ataque card\u00edaco e acidente vascular cerebral. <strong>Al\u00e9m disso,<\/strong> an\u00e1lises secund\u00e1rias inclu\u00edram mudan\u00e7as em biomarcadores inflamat\u00f3rios, como a prote\u00edna C-reativa de alta sensibilidade. Embora o medicamento tenha tido o desempenho esperado em algumas frentes, o objetivo final permaneceu ilus\u00f3rio.<\/p>\n<aside aria-label=\"Living with chronic pain every day?\" class=\"nbn-cta nbn-cta-chronic-pain\" role=\"complementary\">\n<h3 class=\"nbn-cta__headline\">Living with chronic pain every day?<\/h3>\n<p class=\"nbn-cta__context\">Anti-inflammatory strategies with personal follow-up.<\/p>\n<p class=\"nbn-cta__action\"><a class=\"nbn-cta__button\" href=\"https:\/\/backfunnel.com.br\/sfunnel\/16716\/?utm_source=naturalmedical&amp;utm_medium=cta&amp;utm_campaign=chronic-pain&amp;utm_content=mid\" rel=\"noopener noreferrer nofollow sponsored\" target=\"_blank\">Chat on WhatsApp<\/a><\/p>\n<\/aside>\n<h2>Sucesso nos Biomarcadores, Desconex\u00e3o Cl\u00ednica<\/h2>\n<p>O ziltivekimab de fato atingiu seu objetivo secund\u00e1rio: reduziu significativamente os marcadores de inflama\u00e7\u00e3o, confirmou a empresa. <strong>Al\u00e9m disso,<\/strong> reduzir esses biomarcadores \u00e9 muitas vezes considerado um sinal positivo, indicando que o medicamento est\u00e1 atingindo seu alvo biol\u00f3gico. <strong>Por exemplo,<\/strong> em muitos ensaios, essa redu\u00e7\u00e3o espera-se que se traduza em menos eventos cl\u00ednicos. No entanto, este estudo demonstrou que a redu\u00e7\u00e3o da inflama\u00e7\u00e3o no sangue n\u00e3o se traduz necessariamente em uma redu\u00e7\u00e3o do risco de complica\u00e7\u00f5es maiores, incluindo morte cardiovascular, ataque card\u00edaco ou acidente vascular cerebral.<\/p>\n<p>Essa desconex\u00e3o ressalta uma li\u00e7\u00e3o cr\u00edtica no desenvolvimento de medicamentos: desfechos substitutos nem sempre predizem benef\u00edcios no mundo real. <strong>Embora<\/strong> a inflama\u00e7\u00e3o esteja intimamente ligada \u00e0 doen\u00e7a card\u00edaca, a rela\u00e7\u00e3o \u00e9 complexa. <strong>Contudo,<\/strong> \u00e9 poss\u00edvel que os efeitos do ziltivekimab na via da interleucina-6 n\u00e3o tenham sido suficientes para alterar o processo da doen\u00e7a ou que o risco da popula\u00e7\u00e3o do estudo tenha sido impulsionado por fatores que superaram os benef\u00edcios da terapia anti-inflamat\u00f3ria isolada. <strong>Al\u00e9m disso,<\/strong> a fonte n\u00e3o forneceu detalhes sobre a magnitude da redu\u00e7\u00e3o dos biomarcadores ou se algum subgrupo mostrou benef\u00edcio potencial, deixando muitas perguntas sem resposta.<\/p>\n<h2>Implica\u00e7\u00f5es para as Estrat\u00e9gias Anti-inflamat\u00f3rias<\/h2>\n<p>O fracasso do ziltivekimab em atingir seu desfecho prim\u00e1rio provavelmente repercutir\u00e1 na ind\u00fastria farmac\u00eautica. <strong>Por exemplo,<\/strong> v\u00e1rias empresas est\u00e3o investigando inibidores da interleucina-6 e outros agentes anti-inflamat\u00f3rios para preven\u00e7\u00e3o cardiovascular. <strong>Embora<\/strong> este resultado n\u00e3o invalide a hip\u00f3tese da inflama\u00e7\u00e3o, ele modera o entusiasmo e pode redirecionar a pesquisa para terapias mais direcionadas ou abordagens combinadas. <strong>Ademais,<\/strong> isso tamb\u00e9m reafirma que a aterosclerose \u00e9 uma doen\u00e7a multifacetada, onde o colesterol, a press\u00e3o arterial e as vias de coagula\u00e7\u00e3o permanecem alvos essenciais.<\/p>\n<p>Para cl\u00ednicos e pacientes, a not\u00edcia significa que o ziltivekimab n\u00e3o se tornar\u00e1 uma nova ferramenta para o manejo da doen\u00e7a card\u00edaca. <strong>No entanto,<\/strong> isso n\u00e3o diminui a import\u00e2ncia de controlar a inflama\u00e7\u00e3o por outros meios. <strong>Por exemplo,<\/strong> terapias estabelecidas como as estatinas, que t\u00eam propriedades anti-inflamat\u00f3rias, continuam sendo pilares do tratamento. <strong>Al\u00e9m disso,<\/strong> a perspectiva da medicina natural enfatiza que a inflama\u00e7\u00e3o sist\u00eamica muitas vezes pode ser modulada por fatores de estilo de vida, oferecendo um caminho complementar que carece dos riscos das interven\u00e7\u00f5es farmac\u00eauticas.<\/p>\n<h2>Maneiras Hol\u00edsticas e Baseadas em Evid\u00eancias de Reduzir a Inflama\u00e7\u00e3o<\/h2>\n<p>A inflama\u00e7\u00e3o cr\u00f4nica n\u00e3o \u00e9 apenas uma consequ\u00eancia da doen\u00e7a, mas tamb\u00e9m um fator que a impulsiona, e os h\u00e1bitos di\u00e1rios desempenham um papel profundo. <strong>Dessa forma,<\/strong> autoridades de sa\u00fade como a Organiza\u00e7\u00e3o Mundial da Sa\u00fade e a Associa\u00e7\u00e3o Americana do Cora\u00e7\u00e3o recomendam um padr\u00e3o alimentar rico em frutas, vegetais, gr\u00e3os integrais e \u00e1cidos graxos \u00f4mega-3 para ajudar a manter a inflama\u00e7\u00e3o sob controle. <strong>Al\u00e9m disso,<\/strong> a dieta mediterr\u00e2nea, em particular, foi associada a n\u00edveis mais baixos de marcadores inflamat\u00f3rios em numerosos estudos observacionais. <strong>Ademais,<\/strong> a atividade f\u00edsica regular, visando pelo menos 150 minutos de exerc\u00edcio moderado por semana, \u00e9 outra estrat\u00e9gia baseada em evid\u00eancias com benef\u00edcios tanto anti-inflamat\u00f3rios quanto cardiovasculares.<\/p>\n<p>A redu\u00e7\u00e3o do estresse por meio da aten\u00e7\u00e3o plena, ioga ou sono adequado tamb\u00e9m pode regular negativamente as vias inflamat\u00f3rias. <strong>Embora<\/strong> essas abordagens n\u00e3o tenham sido testadas com o mesmo rigor dos ensaios farmac\u00eauticos, elas abordam as causas fundamentais da inflama\u00e7\u00e3o impulsionada pelo estilo de vida sem efeitos colaterais. <strong>No entanto,<\/strong> \u00e9 essencial que os pacientes consultem seu profissional de sa\u00fade antes de fazer qualquer mudan\u00e7a significativa, especialmente se tiverem doen\u00e7a card\u00edaca ou renal. <strong>Al\u00e9m disso,<\/strong> nenhum alimento ou suplemento isolado pode substituir o tratamento m\u00e9dico, mas um plano hol\u00edstico pode ser um parceiro valioso para os cuidados convencionais.<\/p>\n<h2>O que os Pacientes Devem Reter<\/h2>\n<p>Para os milh\u00f5es que vivem com doen\u00e7a card\u00edaca e renal, o resultado principal do estudo do ziltivekimab pode ser decepcionante. <strong>No entanto,<\/strong> ele refor\u00e7a a mensagem de que gerenciar os fatores de risco continua sendo o caminho comprovado. <strong>Por exemplo,<\/strong> controle da press\u00e3o arterial, redu\u00e7\u00e3o do colesterol, cessa\u00e7\u00e3o do tabagismo e manejo do diabetes ainda s\u00e3o a base da preven\u00e7\u00e3o. <strong>Al\u00e9m disso,<\/strong> o estudo tamb\u00e9m serve como um lembrete de que altera\u00e7\u00f5es promissoras nos biomarcadores nem sempre garantem prote\u00e7\u00e3o cl\u00ednica e que ensaios robustos s\u00e3o essenciais antes de adotar novas terapias.<\/p>\n<p>O rev\u00e9s da Novo Nordisk ilustra os desafios do desenvolvimento de medicamentos, <strong>mas<\/strong> tamb\u00e9m oferece uma oportunidade para refletir sobre o poder das abordagens integrativas. <strong>Dessa forma,<\/strong> ao combinar tratamentos m\u00e9dicos com estilos de vida naturais e anti-inflamat\u00f3rios, os pacientes podem abordar sua sa\u00fade de v\u00e1rios \u00e2ngulos. <strong>Como sempre,<\/strong> qualquer decis\u00e3o sobre tratamento deve ser tomada em parceria com um profissional de sa\u00fade qualificado que possa adaptar as recomenda\u00e7\u00f5es \u00e0s necessidades individuais. <strong>Enquanto isso,<\/strong> a busca por melhores medicamentos para o cora\u00e7\u00e3o continua, mas, por enquanto, as ferramentas anti-inflamat\u00f3rias mais seguras j\u00e1 podem estar em nossos pratos e em nossas rotinas di\u00e1rias.<\/p>\n<aside aria-label=\"Living with chronic pain every day?\" class=\"nbn-cta nbn-cta-chronic-pain\" role=\"complementary\">\n<h3 class=\"nbn-cta__headline\">Living with chronic pain every day?<\/h3>\n<p class=\"nbn-cta__context\">Anti-inflammatory strategies with personal follow-up.<\/p>\n<p class=\"nbn-cta__action\"><a class=\"nbn-cta__button\" href=\"https:\/\/backfunnel.com.br\/sfunnel\/16716\/?utm_source=naturalmedical&amp;utm_medium=cta&amp;utm_campaign=chronic-pain&amp;utm_content=end\" rel=\"noopener noreferrer nofollow sponsored\" target=\"_blank\">Chat on WhatsApp<\/a><\/p>\n<\/aside>\n<section class=\"faq-section\">\n<h2>Frequently Asked Questions<\/h2>\n<h3>What was the outcome of Novo Nordisk&#8217;s Phase 3 trial of ziltivekimab for heart disease?<\/h3>\n<p>Novo Nordisk said that ziltivekimab did not reduce the risk of major heart events in the pivotal trial, even though it lowered markers of inflammation.<\/p>\n<h3>How many participants were enrolled in the ziltivekimab heart disease study?<\/h3>\n<p>The Phase 3 study enrolled over 6,300 people with heart disease, kidney disease, and inflammation.<\/p>\n<h3>Did ziltivekimab&#8217;s reduction of inflammation markers lead to fewer major heart complications?<\/h3>\n<p>No, the lowering of inflammation markers did not translate into a reduction in risk of major complications, including cardiovascular-related death, heart attack, or stroke.<\/p>\n<\/section>\n<section class=\"newsbot-related-posts\">\n<h2>Read Also<\/h2>\n<ul>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/fiber-supplement-knee-arthritis-relieves\/\"><strong>Fiber supplement relieves knee arthritis pain, trial finds<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/systemic-capillary-leak-syndrome-colorado\/\"><strong>Colorado Dad warns of Systemic Capillary Leak Syndrome<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/hip-arthritis-exercise-review-finds\/\"><strong>Review Finds Small Benefits of Exercise for Hip Arthritis<\/strong><\/a><\/li>\n<\/ul>\n<\/section>\n<h2>Source<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.statnews.com\/2026\/07\/31\/novo-nordisk-inflammation-heart-disease-ziltivekimab\/?utm_campaign=rss\" rel=\"nofollow noopener\" target=\"_blank\">www.statnews.com<\/a><\/li>\n<\/ul>\n<section class=\"author-box\" style=\"border:1px solid #e5e7eb;background:#f9fafb;padding:16px 20px;margin:24px 0;border-radius:6px;font-size:0.95em;color:#1f2937\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;color:#111827\">About the author<\/h3>\n<p style=\"margin:0 0 6px 0\"><strong>Natural Medical Post Editorial Team<\/strong> &mdash; <em>Health &amp; Wellness Research Team<\/em><\/p>\n<p style=\"margin:0\">Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>On Friday, Novo Nordisk announced that its anti-inflammatory drug ziltivekimab did not reduce major cardiovascular events in a pivotal Phase 3 trial, despite lowering inflammation markers. The study included over 6,300 people with heart disease, kidney disease, and chronic inflammation.<\/p>\n","protected":false},"author":1,"featured_media":3129,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_newsbot_seo_title":"Novo Nordisk's Ziltivekimab fails heart disease trial","_newsbot_seo_description":"Novo Nordisk\u2019s ziltivekimab lowered inflammation markers but failed to reduce major heart events in a Phase 3 study of over 6,300 patients with heart and kidney disease. Learn what this means for anti-inflammatory treatments and holistic heart health.","_newsbot_seo_canonical":"https:\/\/naturalmedicalpost.com\/blog\/ziltivekimab-novo-nordisk-s-fails","_newsbot_seo_og_image":"https:\/\/www.statnews.com\/wp-content\/uploads\/2025\/10\/GettyImages-2197227349-1024x576.jpg","_newsbot_schema_json":"{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"headline\": \"Novo Nordisk\u2019s Anti-inflammatory Drug Ziltivekimab Fails to Reduce Heart Events in Pivotal Trial\", \"description\": \"Novo Nordisk announced that ziltivekimab did not reduce major cardiovascular events in a Phase 3 trial, despite lowering inflammation markers. The study enrolled over 6,300 patients with heart and kidney disease.\", \"inLanguage\": \"en\", \"isAccessibleForFree\": true, \"wordCount\": 850, \"author\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"mainEntityOfPage\": \"https:\/\/naturalmedicalpost.com\/blog\", \"datePublished\": \"2026-07-31T23:22:39.784236+00:00\", \"dateModified\": \"2026-07-31T23:22:39.784236+00:00\", \"about\": \"ziltivekimab\", \"keywords\": [\"ziltivekimab\", \"Chronic Pain\"], \"image\": {\"@type\": \"ImageObject\", \"url\": \"https:\/\/www.statnews.com\/wp-content\/uploads\/2025\/10\/GettyImages-2197227349-1024x576.jpg\"}, \"speakable\": {\"@type\": \"SpeakableSpecification\", \"cssSelector\": [\".article-lede\", \"h1\", \"meta[name='description']\"]}}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"BreadcrumbList\", \"itemListElement\": [{\"@type\": \"ListItem\", \"position\": 1, \"name\": \"Natural Medical Post\", \"item\": \"https:\/\/naturalmedicalpost.com\/blog\"}, {\"@type\": \"ListItem\", \"position\": 2, \"name\": \"Chronic Pain\", \"item\": \"https:\/\/naturalmedicalpost.com\/blog\/chronic-pain\"}, {\"@type\": \"ListItem\", \"position\": 3, \"name\": \"Novo Nordisk's Ziltivekimab fails heart disease trial\"}]}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"What was the outcome of Novo Nordisk's Phase 3 trial of ziltivekimab for heart disease?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Novo Nordisk said that ziltivekimab did not reduce the risk of major heart events in the pivotal trial, even though it lowered markers of inflammation.\"}}, {\"@type\": \"Question\", \"name\": \"How many participants were enrolled in the ziltivekimab heart disease study?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"The Phase 3 study enrolled over 6,300 people with heart disease, kidney disease, and inflammation.\"}}, {\"@type\": \"Question\", \"name\": \"Did ziltivekimab's reduction of inflammation markers lead to fewer major heart complications?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"No, the lowering of inflammation markers did not translate into a reduction in risk of major complications, including cardiovascular-related death, heart attack, or stroke.\"}}]}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"MedicalWebPage\", \"name\": \"Novo Nordisk's Ziltivekimab fails heart disease trial\", \"about\": {\"@type\": \"MedicalCondition\", \"name\": \"Chronic Pain\"}, \"inLanguage\": \"en\", \"lastReviewed\": \"2026-07-31T23:25:21.958454+00:00\", \"reviewedBy\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"url\": \"https:\/\/naturalmedicalpost.com\/blog\"}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"QAPage\", \"mainEntity\": {\"@type\": \"Question\", \"name\": \"What was the outcome of Novo Nordisk's Phase 3 trial of ziltivekimab for heart disease?\", \"answerCount\": 1, \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Novo Nordisk said that ziltivekimab did not reduce the risk of major heart events in the pivotal trial, even though it lowered markers of inflammation.\"}}}, {\"author\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post Editorial Team\", \"jobTitle\": \"Health &amp; Wellness Research Team\", \"description\": \"Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.\"}, \"reviewedBy\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post Editorial Team\", \"jobTitle\": \"Health &amp; Wellness Research Team\", \"description\": \"Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.\"}, \"lastReviewed\": \"2026-07-31T23:25:21.958491+00:00\"}]}","_newsbot_quality_score":"100","_newsbot_quality_grade":"A+","footnotes":""},"categories":[57],"tags":[],"class_list":["post-3127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chronic-pain"],"views":0,"_links":{"self":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/comments?post=3127"}],"version-history":[{"count":1,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3127\/revisions"}],"predecessor-version":[{"id":3128,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3127\/revisions\/3128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/media\/3129"}],"wp:attachment":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/media?parent=3127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/categories?post=3127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/tags?post=3127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}